News Column

Sernova Receives Patent Allowance for Cell Pouch and Therapeutic Cell Transplantation Technologies

May 26, 2014



By a News Reporter-Staff News Editor at Diabetes Week -- Sernova Corp. (TSX VENTURE:SVA), announced that the Australian Patent Office has issued a Notice of Acceptance to Sernova for its patent application entitled "Methods and Devices for Cellular Transplantation."

This patent covers Sernova's entire Cell Pouch™ system of therapeutic cells, the Cell Pouch™ and its surgical tools for cell transplantation. The allowance of this patent will provide Sernova with patent protection through 2030. Similar patent applications have been filed in multiple countries around the world and have a higher likelihood of being granted now that the Australian one has been allowed.

"With this patent allowance, Sernova is now advancing to secure exclusive patent rights globally of our core technologies," stated Dr. Philip Toleikis, Sernova's President and CEO. "This patent allowance is timely as intellectual property is a key element in attracting partners, which is the focus of our new world-class business development team."

"The transition of intellectual property from a patent application to an allowed patent is a key component in strengthening the valuation of a technology", said Kevin Egan, Chair of Sernova'sBusiness Advisory Board. "The fact that Sernova has achieved this for its platform technologies significantly increases its value and potential to partner with a major pharmaceutical or medical device company."

When transplanted into Sernova's Cell Pouch™, a safe, protected and efficacious environment is provided for therapeutic cells such as insulin-producing islets for the treatment of diabetes, as demonstrated in multiple preclinical studies.

In human patients with diabetes, the Cell Pouch™, transplanted with insulin producing islets, in interim analyses, has been shown to be biocompatible and safe as the primary objective of a clinical study at the University of Alberta with Dr. James Shapiro as principal investigator.

Sernova is exploring the additional utility of the Cell Pouch™ an enabling platform for a range of diseases such as haemophilia with Medicyte Gmbh and to maintain calcium homeostasis in kidney disease through parathyroid gland transplantation (see also Therapeutics).

Keywords for this news article include: Technology, Therapeutics.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Diabetes Week